Abstract 141P
Background
Immunotherapy based on Immune Checkpoint Inhibitors (ICI) has changed the management of advanced Non-Small Cell Lung Cancer (NSCLC), achieving long-time responders for the first time. However, response rates remain below 40%. A deeper understanding of ICI response mechanisms and the identification of predictive biomarkers is still an urgent need. A close relation between DNA methylation and the immunogenic status of the tumor microenvironment (TME) has been recently proposed for several solid tumors. In this work we evaluated the epigenetic and transcriptomic status of NSCLC tumors before immunotherapy to disclose the possible role of DNA methylation in ICI response, and to identify immune-related signatures that predict ICI outcome.
Methods
We included 24 advanced NSCLC patients treated with anti-PD1 at first line. DNA and RNA were extracted from FFPE tumor biopsies. Genome-wide DNA methylation was quantified with the MethylationEPIC array and RNA-seq was performed with a NovaSeq6000 system. Data was annotated to the GRCh38 genome and bioinformatics was performed with R/Bioconductor.
Results
Differential methylation and expression patterns were found between patients with radiological response (n=10) and non-responder patients (n=14). We identified a DNA methylation signature that predicts a 6-months response to anti-PD1 therapy. Also, we reported a methylation profile associated with longer progression-free survival (PFS). Functional consequences of differential DNA methylation were confirmed by RNA-seq, identifying dysregulated immune pathways significantly enriched for both methylation and transcriptomic signatures. Pathways associated to ICI response related to T-cell and toll-like receptors signaling pathways, MHC-II complex, and interleukins. We also found aberrant methylation of the PI3K-Akt signaling pathway, which plays an essential role in the TME, regulating immune checkpoints and the sensitivity to ICI.
Conclusions
Overall, our results confirm that DNA methylation plays a role in the response to ICI in advanced NSCLC. These immune-related methylation profiles can predict response to anti-PD1 therapy and correlate with longer PFS, representing a source of predictive biomarkers for ICI outcome.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This research project is funded by the national Institute of Health Carlos III (ISCIII, PI21/00348). M.M-F. is supported by the Miguel Servet program (CP20/00188) from the ISCIII and the European Social Fund (“Investing in your future”).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia
Presenter: Tatyana Abakumova
Session: Cocktail & Poster Display session
Resources:
Abstract
63P - The impact of disruption of melatonin secretion on the structural-functional changes of the microbiome and the role of the melatonin-microbiome axis in the initiation of carcinogenesis
Presenter: Alexandre Tavartkiladze
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Acidosis induces ferroptosis of breast cancer via ZFAND5/SLC3A2 axis with the synergistic effect of metformin and facilitates M1 macrophage polarization
Presenter: Hanchu Xiong
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Transmembrane distribution of phosphatidylethanolamine in plasma membrane of ovarian cancer cells under conditions mimicking tumor microenvironment
Presenter: Darya Savenkova
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma
Presenter: Liam Wilson
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - The role of systemic reprogramming of GMPs in improving outcomes in glioblastoma
Presenter: Aline Atallah
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Integrated OMIC analysis reveals arginine and proline metabolism plays critical role in hypoxia-induced oral squamous cell carcinoma
Presenter: Avinash Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Individualising methotrexate dose based on MTHFR gene polymorphisms in acute lymphoblastic leukemia
Presenter: Meher Konatam
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer
Presenter: Sandro Surmava
Session: Cocktail & Poster Display session
Resources:
Abstract